Physician profile
Benjamin G Chang
NPI 1669467023
$1,372.35
in general payments reported to CMS, 2019-2025
25 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $121 · 2022: $50.71 · 2023: $15.27 · 2024: $22.60 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $184.00 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Glaxosmithkline, LLC. | $170.72 | 2019-2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $116.73 | 2019 | |
| Insmed, INC. | $97.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $82.78 | 2019-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.68 | 2019 | |
| Amgen INC. | $70.56 | 2025 | Tezspire |
| Novo Nordisk INC | $49.48 | 2019-2024 | |
| Harmony Biosciences LLC | $48.97 | 2020-2025 | |
| Philips North America LLC | $48.52 | 2019 | |
| Electromed, INC. | $44.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.20 | 2019-2020 | |
| Pfizer INC. | $43.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.19 | 2022-2023 | Eliquis |
| Viatris Specialty LLC | $32.06 | 2025 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $31.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.71 | 2019 | |
| Circassia INC. | $28.77 | 2019 | |
| Abbvie INC. | $26.79 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $26.51 | 2025 | Opsumit |
| Novartis Pharmaceuticals Corporation | $20.00 | 2019 | |
| Genentech USA, INC. | $19.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.62 | 2019 | |
| Amarin Pharma, INC. | $11.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.